---
layout: post
title: "Real-Time Oncology Review; Guidance for Industry; Availability"
date: 2026-02-05 18:57:28 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-24712
original_published: 2023-11-08 00:00:00 +0000
significance: 8.00
---

# Real-Time Oncology Review; Guidance for Industry; Availability

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** November 08, 2023 00:00 UTC
**Document Number:** 2023-24712

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Real-Time Oncology Review (RTOR)." The purpose of this guidance is to provide recommendations to applicants on the process for submission of selected new drug applications (NDAs) and biologics license applications (BLAs) with oncology indications for review under RTOR. This guidance finalizes the draft guidance of the same title issued on July 22, 2022.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/11/08/2023-24712/real-time-oncology-review-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2023-24712

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
